Jane Street Group LLC Takes $600,000 Position in Septerna, Inc. (NASDAQ:SEPN)

Jane Street Group LLC bought a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 26,208 shares of the company's stock, valued at approximately $600,000. Jane Street Group LLC owned about 0.06% of Septerna as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Samsara BioCapital LLC acquired a new position in shares of Septerna in the fourth quarter worth approximately $63,399,000. Soros Fund Management LLC acquired a new position in shares of Septerna in the fourth quarter worth approximately $229,000. Northern Trust Corp acquired a new position in Septerna in the fourth quarter valued at approximately $3,384,000. The Manufacturers Life Insurance Company acquired a new position in Septerna in the fourth quarter valued at approximately $506,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Septerna in the fourth quarter valued at approximately $6,870,000.

Septerna Stock Down 4.7%

Shares of SEPN stock traded down $0.46 on Friday, hitting $9.40. 793,275 shares of the stock were exchanged, compared to its average volume of 712,049. The firm's 50 day moving average is $7.07 and its two-hundred day moving average is $13.15. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $0.22 million during the quarter. As a group, equities research analysts predict that Septerna, Inc. will post -7.11 earnings per share for the current year.

Wall Street Analyst Weigh In

SEPN has been the topic of several recent analyst reports. Wells Fargo & Company boosted their price target on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research note on Friday, May 16th. Cantor Fitzgerald boosted their price objective on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th.

Insiders Place Their Bets

In other news, Director Alan Ezekowitz bought 7,491 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was acquired at an average price of $6.35 per share, with a total value of $47,567.85. Following the completion of the purchase, the director now directly owns 24,911 shares in the company, valued at $158,184.85. This represents a 43.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.30% of the stock is owned by insiders.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.